45 CFR § 180 compliance
F · 55
This hospital published little of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
○Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
16,105
Insurances with rates
2
CPT / HCPCS codes
12,475
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| Q2042 | tisagenlecleucel-T Suspension 1 Each Flex Cont | $2,719,138 | $1,495,526 | — | — | 5 |
| Q2056 | ciltacabtagene autoleucel 100000000 CELLS Suspension 1 Each Bag | $2,394,750 | $1,317,113 | — | — | 5 |
| Q2041 | axicabtagene ciloleucel Suspension 1 Each Package | $2,310,000 | $1,270,500 | — | — | 5 |
| Q2055 | idecabtagene vicleucel 460000000 CELLS Suspension 1 Each Bag | $2,286,275 | $1,257,451 | — | — | 5 |
| Q2054 | lisocabtagene maraleucel CD8 Suspension 1 Each Vial | $2,236,135 | $1,229,874 | — | — | 3 |
| Q2053 | brexucabtagene autoleucel 200000000 CELLS Suspension 1 Each Flex Cont | $2,120,000 | $1,166,000 | — | — | 5 |
| J2326 | nusinersen 12 MG/5ML Solution 5 mL Vial | $599,841 | $329,912 | — | — | 5 |
| J0225 | vutrisiran 25 MG/0.5ML Solution Prefilled Syringe 0.5 mL Syringe | $486,685 | $267,677 | — | — | 5 |
| J1823 | inebilizumab-cdon 100 MG/10ML Solution 10 mL Vial | $196,358 | $107,997 | — | — | 5 |
| J2351 | ocrelizumab-hyaluronidase-ocsq 920-23000 mg-unit/23 mL Solution 23 mL Vial | $173,394 | $95,367 | — | — | 5 |
| 0812 | HC KIDNEY ACQUISITION EN BLOC | $173,000 | $95,150 | — | — | 3 |
| 0811 | HC KIDNEY ACQUISITION LIVE | $173,000 | $95,150 | — | — | 3 |
| J9269 | tagraxofusp-erzs 1000 MCG/ML Solution 1 mL Vial | $138,417 | $76,130 | — | — | 5 |
| J2507 | Pegloticase 8 MG/ML Solution 1 mL Vial | $126,104 | $69,357 | — | — | 5 |
| J0202 | alemtuzumab 12 MG/1.2ML Solution 1.2 mL Vial | $123,699 | $68,034 | — | — | 5 |
| J9271 | pembrolizumab 400 mg 400 mg Solution 66 mL Bag | $119,237 | $65,581 | — | — | 9 |
| J1747 | spesolimab-sbzo 450 MG/7.5ML Solution 7.5 mL Vial | $117,204 | $64,462 | — | — | 5 |
| J9359 | loncastuximab tesirine-lpyl 10 mg/2 mL Recon Soln 1 Each Vial | $113,857 | $62,621 | — | — | 5 |
| J9266 | pegaspargase 750 UNIT/ML Solution 5 mL Vial | $109,957 | $60,476 | — | — | 5 |
| J1305 | Evinacumab-dgnb 1200 MG/8ML Solution 8 mL Vial | $105,292 | $57,911 | — | — | 5 |
| J9281 | mitoMYcin 80 (2 x 40) MG Recon Soln 1 Each Box | $100,383 | $55,211 | — | — | 5 |
| J1303 | ravulizumab-cwvz 1100 MG/11ML Solution 11 mL Vial | $98,214 | $54,018 | — | — | 5 |
| J9600 | porfimer Recon Soln 1 Each Vial | $97,967 | $53,882 | — | — | 5 |
| 77371 | HC SRS MULTISOURCE | $97,750 | $53,763 | — | — | 2 |
| J9229 | inotuzumab ozogamicin 0.25 mg/ml Recon Soln 1 Each Vial | $93,938 | $51,666 | — | — | 5 |
| 33289 | HC TRANSCATH IMPL WIRELESS PULM ART PRESS SENSOR FOR L-T HEMODYNAM MONITOR | $92,989 | $51,144 | — | — | 4 |
| J2350 | ocrelizumab 300 MG/10ML Solution 10 mL Vial | $86,702 | $47,686 | — | — | 5 |
| 33270 | HC INSERT REPLC PERM SUBQ IMPLANT DEFIBRILLATOR SYS | $86,072 | $47,340 | — | — | 4 |
| J9274 | Tebentafusp-tebn 100 MCG/0.5ML Solution 0.5 mL Vial | $83,983 | $46,191 | — | — | 5 |
| 63685 | HC INSERT/REPLC SPINAL NRSTIM PLS GEN/RECVR, W PKT CREATION & CONN | $83,887 | $46,138 | — | — | 4 |
| 0571T | HC INSERT/RPLCMT ICDS W/ SUBSTERNAL ELECTRODE INCLD IMG GUID AND EPS EVAL | $81,453 | $44,799 | — | — | 4 |
| J7313 | Fluocinolone Acetonide 0.59 MG Implant 1 Each Package | $79,915 | $43,953 | — | — | 5 |
| J9350 | Mosunetuzumab-axgb 30 MG/30ML Solution 30 mL Vial | $76,798 | $42,239 | — | — | 5 |
| J9309 | polatuzumab vedotin-piiq 20 mg/mL Recon Soln 1 Each Vial | $76,322 | $41,977 | — | — | 10 |
| J3245 | tildrakizumab-asmn 100 MG/ML Solution Prefilled Syringe 1 mL Syringe | $75,448 | $41,496 | — | — | 4 |
| J3241 | teprotumumab-trbw 500 MG Recon Soln 1 Each Vial | $73,557 | $40,456 | — | — | 5 |
| 0624 | HC REPRISE IV TRIAL, LOTUS EDGE VALVE 23MM-27MM IDE G160209 | $73,378 | $40,358 | — | — | 3 |
| J9334 | efgartigimod alfa-hyaluronidase-qvfc 1008-11200 mg-UT/5.6 mL Solution 5.6 mL Vial | $67,582 | $37,170 | — | — | 5 |
| 38240 | HC HEMATOPOIETIC PROGENITOR CELL (HPC) ALLOGENEIC TRANSPLANTATION PER DONOR | $66,111 | $36,361 | — | — | 20 |
| 33263 | HC REM IMPL DEFIB PLSE GEN W REPL IMPL DEFIB PLSE GEN DUAL LEAD | $65,825 | $36,204 | — | — | 4 |
| L5991 | IMPL BIOHELIX 21X80 -12 | $64,575 | $35,516 | — | — | 4 |
| 33340 | HC PERC TRANSCATH CLOSURE LAA W/ ENDOCARDIAL IMPLANT | $63,897 | $35,143 | — | — | 4 |
| J9026 | tarlatamab-dlle 10 MG Recon Soln 1 Each Vial | $63,010 | $34,656 | — | — | 5 |
| 33262 | HC REM IMPL DEFIB PLSE GEN W REPL IMPL DEFIB PLSE GEN SGL LEAD | $62,747 | $34,511 | — | — | 4 |
| J9298 | nivolumab-relatlimab-rmbw 240-80 mg/20mL Solution 20 mL Vial | $62,005 | $34,103 | — | — | 5 |
| J3357 | ustekinumab 45 MG/0.5ML Solution Prefilled Syringe 0.5 mL Syringe | $61,228 | $33,675 | — | — | 5 |
| J1628 | guselkumab 200 MG/20ML Solution 20 mL Vial | $61,189 | $33,654 | — | — | 6 |
| 33264 | HC REM IMPL DEFIB PLSE GEN W REPL IMPL DEFIB PLSE GEN MULT LEAD | $61,148 | $33,631 | — | — | 3 |
| J9307 | PRALAtrexate 40 MG/2ML Solution 2 mL Vial | $60,775 | $33,426 | — | — | 6 |
| J9381 | teplizumab-mzwv 2 MG/2ML Solution 2 mL Vial | $59,100 | $32,505 | — | — | 5 |
Showing top 50 of 16,105 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.